The clinical significance and virulence potential of Enterococcus casseliflavus/flavescens and Enterococcus gallinarum are still uncertain. We retrospectively analyzed 56 cases of significant bacteremia caused by E. casseliflavus or E. gallinarum. Of these cases, 25 (44.6%) were associated with polymicrobial bacteremia, and 43 (76.8%) were associated with entry via the biliary tract. Resistance to vancomycin was observed in 17 (30.4%) of these 56 patients, and this resistance was significantly associated with E. gallinarum bacteremia (adjusted odds ratio [AOR], 10.56; 95% confidence interval [CI], 2.41-46.27) and bacteremia without biliary tract origin (AOR, 6.74; 95% CI, 1.44-31.67). The crude mortality rate was 13%, and the bacteremia-related mortality rate was 1.9%. In conclusion, bacteremia due to E. casseliflavus and E. gallinarum is commonly associated with biliary tract disease and may be associated with a low risk of mortality. $15.00 agar [12] . However, some atypical strains have neither of these characteristics [1, [13] [14] [15] . Precise identification of enterococcal species requires additional tests, including those for methyl-a-D-glucopyranoside acidification [13, 16, 17] , tellurite reduction and ribose fermentation [18, 19] , susceptibility to elfamycin [20], susceptibility to efrotomycin [13] , and molecular assays [1, 15, [21] [22] [23] .
The VanC phenotype enterococci Enterococcus casseliflavus/flavescens and Enterococcus gallinarum are characterized by intrinsic low-level resistance to vancomycin and susceptibility to teicoplanin [1, 2] . The vanC ligase genes, which encode this type of resistance, are known to be not acquired or transferable [3, 4] . To date, these enterococci have not been implicated in a nosocomial outbreak of infection and only occasionally cause clinical disease [5] [6] [7] [8] . They have been considered necessary only for differentiation from other transmissible vancomycin-resistant Enterococcus (VRE) species [9] [10] [11] . However, accurate differentiation of these species from other enterococcal species, particularly Enterococcus faecium, is difficult using conventional biochemical assays. Unlike other enterococcal species, E. casseliflavus/ flavescens and E. gallinarum are typically motile, and E. casseliflavus/flavescens produces a yellow pigment on care-affiliated teaching hospital with 159 intensive care unit (ICU) beds and active programs for liver, pancreas, kidney, heart, and bone marrow transplantation. Blood isolates identified as enterococci since 1 November 1998 were subspeciated on the basis of motility, yellow pigmentation, methyl-a-D-glucopyranoside test results, and acid production from ribose.
Patient selection and data collection. The present study focuses on episodes of significant E. casseliflavus/flavescens and E. gallinarum bacteremia that were diagnosed during the period of November 1998 through April 2003 at Asan Medical Center. Information was obtained from the computerized database of clinical microbiology unit, and patients whose blood culture had yielded E. casseliflavus/flavescens or E. gallinarum were identified. Infectious diseases doctors then reviewed the medical records of these patients and collected data regarding patient demographic characteristics, underlying disease or condition, portal of entry, infecting microorganism, antibiogram findings, manifestations at the time of bacteremia, prior antibiotic use, antibiotic therapy received, and outcome.
Definitions. Clinically significant bacteremia was determined to have occurred if у2 blood cultures yielded E. casseliflavus/flavescens or E. gallinarum or if a single blood culture yielded E. casseliflavus/flavescens or E. gallinarum together with a clinically apparent culture-positive source of infection. The date of onset of bacteremia was defined as the date on which the blood sample was obtained for the first positive culture result. Bacteremia was considered to have been nosocomially acquired if the sample in the positive blood culture was obtained 148 h after admission and if there was no evidence of infection at the time of admission; otherwise, bacteremia was considered to be community acquired. Polymicrobial bacteremia was defined by isolation of 11 organism from the same blood culture specimen. Underlying chronic conditions were classified as "rapidly fatal," "ultimately fatal," or "nonfatal," on the basis of the McCabe and Jackson criteria [33] . Systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock were defined as described elsewhere [34, 35] . A localized infection was accepted as the portal of entry if it was microbiologically and clinically documented. Recurrent bacteremia was defined as the isolation of the same organism from the blood у5 days after initial enterococcal bacteremia. In cases of recurrent bacteremia, only the first episode of Enterococcus bacteremia was included in the analysis. Prior antibiotic use was defined as receipt of antibiotics for у24 h during the previous month. Appropriate therapy was defined as the use of у1 antibiotic to which the organism was susceptible in vitro for 124 h р5 days after the positive blood culture was obtained [36] . Outcome was evaluated at the time of discharge from the hospital. Death was considered to have been related to bacteremia if the patient died р14 days after the onset of bacteremia and if no other cause of death was identified.
Blood culture, species identification, and susceptibility testing. All blood cultures were processed by the hospital microbiology laboratory using a standard blood culturing system (BACTEC 730 or BACTEC 9240; Becton Dickinson). Enterococcus species were identified on the basis of 6.5% NaCl tolerance, bile-esculin hydrolysis, and growth rate at 45ЊC. The species of organism was identified by arginine hydrolysis, motility testing, yellow pigmentation testing, methyl-a-D-glucopyranoside testing, and acid production from ribose. Antibiotic susceptibilities were determined using the Vitek system (bioMérieux-Vitek) or the MicroScan system (Dade Behring), on the basis of standard criteria prescribed by the NCCLS [37] . Intermediate susceptibility to each antibiotic was considered to be resistance.
Statistical analysis. Statistical analysis was performed using the x 2 test or 2-tailed Fisher's exact test for binary variables and the Student's t test or Mann-Whitney U test for continuous scaled variables. Continuous data were expressed as the mean ‫ע‬ SD or as the median and range. Univariate and multivariate analyses to determine independent risk factors for resistance to vancomycin and crude mortality were performed using the logistic regression models. A forward selection was used. Confounders were included in the multivariate analysis if covariate inclusion changed the coefficient of any statistically significant variable in the logistic regression model by у10%.
was considered to be statistically significant. All tests P ! .05 were performed using SPSS software, version 10.0 (SPSS).
RESULTS

Study population.
During the study period, there were 13,891 positive blood culture results, of which Enterococcus species-either alone or in combination with other organisms-were present in 949 (6.8%), yielding an incidence of Enterococcus bacteremia of 3.26 cases per 1000 admissions. E. casseliflavus or E. gallinarum was isolated from 85 cultures (8.9% of all cases of enterococcal bacteremia) for 83 patients. E. flavescens was not detected in any culture. Two patients (2.4%) had recurrent bacteremia with vancomycin-intermediate E. gallinarum. The incidence of bacteremia due to E. casseliflavus or E. gallinarum was 0.29 cases per 1000 admissions. Twenty-seven cases for which a single blood culture yielded E. casseliflavus or E. gallinarum, but for which there was not a culture-positive source of infection, were excluded from the study. Therefore, clinically significant bacteremia was identified in 56 patients.
Microorganisms.
Of the enterococci isolates recovered from these 56 patients (excluding second episodes), 41 (73.2%) were E. casseliflavus and 15 (26.8%) were E. gallinarum. Twentyfive (44.6%) of these patients had polymicrobial bacteremia, and the organisms most frequently observed were gram- Epidemiological data and underlying diseases/conditions. The epidemiological characteristics and underlying disease/conditions of the 56 patients are provided in table 1. Twenty-nine patients (51.8%) were men, and the median age was 59.1 years (range, 21-89 years). All patients had underlying illnesses; the most common underlying illness was biliary disease (75.0%), followed by solid cancer (44.6%). According to the McCabe and Jackson criteria, underlying diseases were nonfatal in 30 patients (53.6%), ultimately fatal in 25 patients (44.6%), and rapidly fatal in 1 patient (1.8%). Among the factors that commonly predisposed patients to bacteremia, 21 patients (37.5%) had biliary drainage catheters in place, 17 (30.4%) had history of prior hospital admission, 7 (12.5%) had leukopenia, and 5 (8.9%) had central venous catheters in place. Twenty-nine (51.8%) of the episodes originated in the hospital, and 27 (48.2%) originated in the community. In cases of hospitalacquired bacteremia at our institution, patients spent a median of 9 days (range, 3-89 days) in the hospital before the development of bacteremia. Three patients (5.4%) were in ICUs at the time of bacteremia. The distribution of all the listed characteristics was not significantly different between patients with E. casseliflavus bacteremia and patients with E. gallinarum bacteremia ( ) were significantly associated with resis-P p .016 tance to vancomycin. Of the 48 tested strains, 5 (10.4%) exhibited high-level resistance to gentamicin, and 1 (2.1%) exhibited high-level resistance to streptomycin. Of the 38 tested strains, all were susceptible to imipenem.
Antibiotic therapy. The treatment regimens are shown in Outcomes. Clinical outcomes are summarized in table 5. The outcomes for 2 patients were not available because the patients were transferred to other hospitals. The crude mortality rate of patients was 13.0% (7 of 54 patients), with only 1 death (1.9%) considered to be related to bacteremia. This patient had pancreas head cancer with concomitant bacteremia due to P. aeruginosa. Multivariate analysis, including analysis with variables with in univariate analysis, showed that bacter-P р .100 emia of non-biliary tract origin was the only significant risk factor for crude mortality (AOR, 8.43; 95% CI, 1.32-54.0). Although the mortality rate was higher among patients with polymicrobial bacteremia (21.7%) than among those with monomicrobial bacteremia (6.5%), this difference was not statistically significant ( ). The median length of hospital P p .122 stay after bacteremia for surviving patients was 22.0 days (range, 5-151 days).
DISCUSSION
We have determined the clinical characteristics and outcomes of patients with bacteremia due to E. casseliflavus and E. gallinarum. These organisms were frequently associated with polymicrobial bacteremia and commonly originated from the biliary tract. The risk of mortality was low, and none of the deaths among the patients with monomicrobial E. casseliflavus and E. gallinarum bacteremia were directly related to bacteremia.
When we compared our results with those of other recent reports on enterococcal bacteremia [25, 28] , we noted similar proportions of enterococcal bacteremia relative to the total episodes of bacteremia (6.8% vs. 5.0%-7.1%). The incidence of all cases of enterococcal bacteremia, however, was higher in our study (3.26 episodes per 1000 admissions) than in other studies (1.6-2.3 cases per 1000 admissions), and the overall proportion of E. casseliflavus or E. gallinarum bacteremia relative to all enterococci bacteremia was much higher in our study (8.9%) than in previous studies (!1%-3%) [27, 28, 31, 32, 38] . This difference may reflect different patient populations, or it may reflect our use of more-accurate processes of bacterial identification.
We found that resistance to vancomycin was significantly more common among E. gallunaum strains than among E. casseliflavus strains, in good agreement with previous results [1, 15, 31, [39] [40] [41] . Recently, Reid et al. [31] reported similar findings. In their study of 20 cases of bacteremia, the MIC was 8 mg/mL for 7 E. gallinarum isolates and for none of the E. casseliflavus isolates. Oral administration of vancomycin has been reported to lead to the emergence of intrinsically vancomycin-resistant gram-positive microorganisms, including E. gallinarum and E. casseliflavus, in the normal intestinal microflora [42] . In our study of 56 patients, only 3 patients received vancomycin before developing enterococcal bacteremia, and none received oral vancomycin. In addition, prior use of vancomycin was not a significant risk factor for resistance to vancomycin among the enrolled patients. However, only a small number of patients in this study had received prior treatment with vancomycin, suggesting that this variable needs further investigation.
Bacteremia with a non-biliary tract origin was another risk factor for resistance to vancomycin-that is, the strains with an origin in the biliary tract were more frequently susceptible to vancomycin. This finding-that bacterial strains demonstrate antibiotic resistance patterns according to the anatomical site of infection-is very unusual. Because VanC VRE is not transmitted between patients, it is unlikely that a greater num- ber of susceptible strains are clustered via the biliary procedure. Currently, we can not explain this clearly. It could be a bias associated with the small number of cases.
We observed a very low mortality rate among our patientsmuch lower than the rates of 20% within 6 days after the onset of bacteremia and 40% within 2 months observed in a previous study [31] . Although the criteria for patient enrollment were similar, our lower mortality rate may be the result of differences in patient populations and distributions of portals of entry. For example, serious underlying conditions were more common in the patients described by Reid et al. [31] than in those described here, including malignancy (70% vs. 44.6%), receipt of a solid-organ transplant (15% vs. 5.4%), and receipt of a bone marrow transplant (10% vs. 0%). The most common portal of entry in our patients was biliary disease (76.8%), in which adequate drainage frequently relieved the septic conditions. In the study by Reid et al. [31] , 35% of the cases were primary bacteremia (the rate was 16.1% in our study). Although precise data were not given, a substantial proportion of the cases of bacteremia were considered to have an origin in the hepatobiliary tract, but this may have been much less common than in our study. When mortality rates from our study were compared with those from other studies of enterococcal bacteremia (crude mortality, 27%-65% for E. faecalis and 29%-76% for E. faecium; bacteremia-related mortality, 11%-13% for E. faecalis and 6%-50% for E. faecium) [29, [43] [44] [45] [46] [47] [48] [49] [50] [51] , the rates were found to be much lower in our series (crude mortality, 13.0%; bacteremia-related mortality, 1.9%). Although many of these differences may be associated with the different patient populations and distributions of portals of entry, it can be assumed that E. casseliflavus and E. gallinarum are no more virulent than is E. faecalis or E. faecium.
Our study had several limitations. First, because it was retrospective in design, isolates were not available for molecular typing; thus, the clonality and genotype of isolates could not be examined. Second, our laboratory did not check for susceptibility to teicoplanin. Dutka-Malen et al. [52] reported the isolation of E. casseliflavus and E. gallinarum strains that were resistant to high levels of vancomycin (MIC, 1256 mg/mL) and teicoplanin (MIC, у64 mg/mL), and there have been reports that VanC VRE strains also have the ability to acquire vanA or vanB genes coding for high-level resistance [22, 52, 53] . Although the phenotype of our isolates could not be determined accurately, the majority (15 of 17) of our vancomycin-nonsusceptible strains were actually intermediately resistant to vancomycin (MIC, 8 mg/mL), suggesting that, at most, only a small number of isolates acquired vanA or vanB genes. Finally, we evaluated the adequacy of antibiotic therapy using the in vitro breakpoint prescribed by NCCLS. Vancomycin therapy for strains with MICs of р4 mg/mL was regarded as adequate. The VanC phenotype is thought to be chromosomally encoded and expressed constitutively. However, some data suggest that it may be inducible in some strains [54, 55] , and there have been several reports of failure or breakthrough bacteremia during vancomycin therapy with in vitro susceptible strains [31, 32] . In general, vancomycin therapy against VanC VRE infection has been regarded as inadequate. Five of our patients received vancomycin monotherapy, and all were alive and without recurrent bacteremia. However, 4 patients with bacteremia originating in the biliary tract underwent subsequent drainage procedures. We would not recommend vancomycin therapy for VanC VRE infection, even for strains that are susceptible in vitro.
In conclusion, our results suggest that bacteremia due to E. casseliflavus and E. gallinarum is commonly associated with biliary tract disease and appears to be associated with a low risk of mortality.
